PCI Biotech Holding ASA (LTS:0JGL) Market Cap: kr2.69 Mil (As of Jul. 04, 2026)


What is PCI Biotech Holding ASA Market Cap?

PCI Biotech Holding ASA LTS:0JGL Market Cap is kr2.69 Mil as of Jul. 04, 2026. The stock has 1 warning sign investors should review.

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). PCI Biotech Holding ASA's share price for the quarter that ended in Jun. 2025 was kr1.665. PCI Biotech Holding ASA's Shares Outstanding (EOP) for the quarter that ended in Jun. 2025 was 37.33 Mil. Therefore, PCI Biotech Holding ASA's market cap for the quarter that ended in Jun. 2025 was kr62.15 Mil.

PCI Biotech Holding ASA's quarterly market cap declined from Jun. 2024 (kr105.26 Mil) to Dec. 2024 (kr67.11 Mil) and declined from Dec. 2024 (kr67.11 Mil) to Jun. 2025 (kr62.15 Mil).

PCI Biotech Holding ASA's annual market cap increased from Dec. 2022 (kr96.67 Mil) to Dec. 2023 (kr105.26 Mil) but then declined from Dec. 2023 (kr105.26 Mil) to Dec. 2024 (kr67.11 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. PCI Biotech Holding ASA's Enterprise Value for Today is kr-10.65 Mil.

PCI Biotech Holding ASA  (LTS:0JGL) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.

PCI Biotech Holding ASA Market Cap Related Terms

PCI Biotech Holding ASA Market Cap Historical Data

* Premium members only.

The historical data trend for PCI Biotech Holding ASA's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PCI Biotech Holding ASA Market Cap Chart

PCI Biotech Holding ASA Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,024.60 421.41 96.67 105.26 67.11

PCI Biotech Holding ASA Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 105.26 105.26 105.26 67.11 62.15

LTS:0JGL vs VRTX, REGN, ALNY: Market Cap Comparison

For the Biotechnology subindustry, PCI Biotech Holding ASA's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PCI Biotech Holding ASA Market Cap vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PCI Biotech Holding ASA's Market Cap distribution charts can be found below:

* The bar in red indicates where PCI Biotech Holding ASA's Market Cap falls into.


PCI Biotech Holding ASA Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

PCI Biotech Holding ASA's Market Cap for the fiscal year that ended in Dec. 2024 is calculated as

Market Cap (A: Dec. 2024 )=Share Price (A: Dec. 2024 )*Shares Outstanding (EOP) (A: Dec. 2024 )
=kr1.798*37.326
=kr67.11

PCI Biotech Holding ASA's Market Cap for the quarter that ended in Jun. 2025 is calculated as

Market Cap (Q: Jun. 2025 )=Share Price (Q: Jun. 2025 )*Shares Outstanding (EOP) (Q: Jun. 2025 )
=kr1.665*37.326
=kr62.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Market Cap →
What does a Market Cap of kr2.69 Mil mean?
PCI Biotech Holding ASA (LTS:0JGL) has a Market Cap of kr2.69 Mil as of Jul. 04, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on PCI Biotech Holding ASA and its competitors.
Is PCI Biotech Holding ASA's Market Cap too high?
PCI Biotech Holding ASA's current Market Cap is kr2.69 Mil.
How does PCI Biotech Holding ASA's Market Cap compare to VRTX and REGN?
PCI Biotech Holding ASA's Market Cap of kr2.69 Mil can be compared against companies in the Biotechnology industry. The industry median Market Cap is 119.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.23, based on 1,426 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on PCI Biotech Holding ASA and its competitors. For the Biotechnology industry, the median Market Cap is 119.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PCI Biotech Holding ASA's current Market Cap is kr2.69 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PCI Biotech Holding ASA stock overvalued right now?
PCI Biotech Holding ASA (LTS:0JGL) has a current Market Cap of kr2.69 Mil. The current Market Cap is kr2.69 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For PCI Biotech Holding ASA (LTS:0JGL), the current Market Cap is kr2.69 Mil as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PCI Biotech Holding ASA Business Description

Address Ullernchausseen 64, Oslo, NOR, N-0379
PCI Biotech Holding ASA is a biopharmaceutical company focused on developing and commercializing cancer therapies using its photochemical internalization (PCI) technology platform. The PCI technology utilizes light to trigger the release of compounds from within cellular compartments. The company applies PCI to three different approaches for cancer treatment: fimaCHEM: Enhancing chemotherapeutic drugs for localized cancer treatment. fimaVACC: Inducing T-cell responses for therapeutic cancer vaccination. fimaNAc: Delivering nucleic acid therapeutics. The key product candidate is fimaporfin (Amphinex), a photosensitizer that can unlock intracellular compartments where active compounds are trapped. The company's sole operating segment is research and development.